Search our science

Search our scientific publications and resources
on rare bleeding disorders

Molecule
Study Phase
Content Type


Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.

 

Search Results

We found 384 resources matching your search criteria

Abstract

Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Oral presentation

Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Poster

Eichler H, Angchaisuksiri P, Astermark J, Benson G, Cepo K, Chowdary P, Hansen T, Kavakli K, Wheeler AP, Oldenburg J. Safety and longer-term efficacy of concizumab prophylaxis in patients with severe haemophilia A without inhibitors: Results from the extension part of the phase 2 explorer5 Trial . Haemophilia. 2021;27(S2): 95. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Review article

Walsh C, Boggio L, Brown-Jones L, Miller R, Hawk S, Savage B, Hansen K, Molter D, Baumann K, Dunn S, Skinner M, Haugstad K, Johnson S, Davenport T, Bradbury M, Witkop M, Saad H, Cooper DL. Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: a summary of opinions from a roundtable of haemophilia experts. Haemophilia. 2021;27(Suppl. 1): 25-32. doi:https://doi.org/10.1111/hae.14168 https://onlinelibrary.wiley.com/doi/10.1111/hae.14168

Primary manuscript

Benson G, Morton T, Thomas H, Lee XY . Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. Clinicoecon Outcomes Res. 2021;13: 39-51. doi:https://doi.org/10.2147/CEOR.S280574

Audio poster
Vance MacDonald, Xin Ying Lee, Alexandre Caillaud, Maria Luckevich, Anthony Bentley; Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch. Blood 2020; 136 (Supplement 1): 19. doi: https://doi.org/10.1182/blood-2020-134236

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to www.novonordisk.com